Psychedelic Medicine


Exploring the Potential of 5-MeO-DMT

Log in To Watch the Recording

*Exclusive for members.

Thursday, April 25th at 5 pm Pacific, 8 pm Eastern >> Log in to Watch the Recording >>

An EXCLUSIVE Panel Discussion For Members Of The Psychedelic Medicine Association:

Exploring the Potential of 5-MeO-DMT


Lynn Marie Morski, MD, JD

Lynn Marie Morski, MD, JD

President, Psychedelic Medicine Association


Manesh Girn, PhD

Manesh Girn, PhD

Postdoctoral Neuroscientist

Dr. Manesh Girn is a postdoctoral neuroscientist and popular science content creator specializing in the neuroscience of psychedelic drugs. He currently works at the University of California, San Francisco, alongside psychedelic research pioneer Dr. Robin Carhart-Harris, where he conducts research on the neural mechanisms underlying the psychedelic experience and psychedelic-assisted psychotherapy. He has been lead or co-author of over 20 peer-reviewed publications to date on topics including psychedelics, the default mode network, abstract cognitive processes, and brain network organization. In addition to his research, Manesh runs a popular digital platform on Instagram and YouTube called “The Psychedelic Scientist”, where he shares the latest findings in psychedelic science in a digestible and easy to understand way. Finally, Manesh serves as the Chief Research Officer at EntheoTech Bioscience, a pioneering Canadian bioscience company focused on psychedelic-assisted psychotherapy and multidisciplinary mental health solutions.

Victoria Wueschner

Victoria Wueschner

President & Co-Founder, F.I.V.E.

Specializing in 5-MeO-DMT, Victoria has dedicated her path to cultivating safe and effective approaches to working with the molecule. After being immersed in the psychedelic space for well over a decade honoring her own path, Victoria stepped into the role of medicine facilitator where she chose to work primarily with 5-MeO-DMT. After immersing herself in the 5-MeO community and multiple trainings, she began her work as a retreat leader at Tandava Retreats in Mexico.

In addition to leading retreats, Victoria is also the co-founder and president of F.I.V.E (5-MeO-DMT Information and Vital Education), a harm reduction platform focused on education, training, research and more. Her aim is to bring awareness to the ethics, integrity, and safety of 5-MeO-DMT. As a result, she collaborated with top experts in the field to develop the worlds most comprehensive 5-MeO-DMT training program, where she currently serves as an educator.

Rebecca Kronman, LCSW

Founder, Plant Parenthood

Rebecca Kronman, LCSW is a licensed therapist and founder of Plant Parenthood, a digital and in-person community of parents who use psychedelics. She is also an assisting trainer with Fluence, a company that trains healthcare practitioners in harm reduction informed psychedelic preparation and integration. At her private practice in Brooklyn, she works with creative professionals using mindfulness and experiential techniques to address depression, anxiety and life transitions. She also helps clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. Selected trainings include Mindfulness Based Stress Reduction, Mindfulness for Clinicians, Psychedelics 101 & 102 and Beyond Experience Psychedelic Integration Workshop.

Reid Robison, MD, MBA

Chief Medical Officer at Novamind/Co-founder at Cedar Psychiatry

Dr. Reid Robison is a board-certified psychiatrist and Chief Medical Officer at Novamind. Reid is co-founder at Cedar Psychiatry and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.

Research showing the potential of 5-MeO-DMT in addressing treatment-resistant depression has recently produced phase II results showing that the compound has rapid antidepressant effects as early as the day after dosing. 

Further studies on 5-MeO-DMT are being conducted to investigate the potential for the drug (combined with psychotherapy) to help address alcohol use disorder as well.

As 5-MeO-DMT is one of the lesser-discussed and less widely known psychedelic medicines, we wanted to bring you, our respected members, a deep dive into the medicine so that as new study results come out, you are more familiar with what 5-MeO-DMT is and how it works.

This month we are truly fortunate to have panelists who have expertise in 5-MeO-DMT. They’ll be discussing the following:

  • The pharmacology and neuroscience of 5-MeO-DMT  
  • 5-MeO-DMT’s effect on neuroplasticity
  • How 5-MeO-DMT is administered
  • Training 5-MeO-DMT facilitators

…and much more!

So please join us for this live panel discussion on Thursday, April 25th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. And for members, please register for the panel here. A link to the recording will be available afterward if you cannot make it to the live event.

You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.